{
    "title": "115_hr5687",
    "content": "The Act titled \"Securing Opioids and Unused Narcotics with Deliberate Disposal and Packaging Act of 2018\" or the \"SOUND Disposal and Packaging Act\" introduces safety-enhancing packaging and disposal features for certain drugs. The Secretary may issue orders requiring the implementation of technologies to reduce drug abuse risks for specific drugs listed in applications, after consulting with stakeholders to ensure access and minimize burden. The order issued by the Secretary may include options for implementing technologies to reduce drug abuse risks, ensuring they are commensurate with the specific risk of abuse, not overly burdensome on patient access, and reduce the risk of abuse or misuse of the drug. The Secretary may issue orders providing options for implementing technologies to reduce drug abuse risks, including referencing packaging or disposal standards. Orders can apply to a pharmacological class after consultation with stakeholders. Compliance is required by the holder of a covered application. The Secretary may issue orders for drug classes to address abuse risks, with compliance required from the holder of a covered application within a specified timeframe. The Secretary may issue orders for drug classes to address abuse risks, with compliance required within specified timeframes for requested alternative dates or changes approved in supplements. Compliance must be implemented within 90 calendar days of supplement approval or a longer period approved by the Secretary upon request. The holder of the covered application may propose alternative technologies, controls, or measures for packaging, storage, or disposal if supported by data to mitigate abuse risk. Disputes related to submitted supplements can be resolved through a process outlined by the Secretary. The holder of a covered application can propose alternative technologies, controls, or measures to mitigate abuse risk. Disputes related to submitted supplements can be resolved through procedures specified by the Secretary. Definitions for terms like 'covered application' and 'relevant stakeholders' are provided in this section. The Public Health Service Act allows for approval of drugs containing opioids listed in schedule II or III under the Controlled Substances Act. Relevant stakeholders may include various experts and organizations in the drug industry, healthcare, and government agencies. Prohibited acts under the Federal Food, Drug, and Cosmetic Act are amended to address these issues. The Federal Food, Drug, and Cosmetic Act is amended to address issues related to drugs containing opioids listed in schedule II or III. This includes requirements for drug approval under a covered application and the content of an Abbreviated New Drug Application. The Federal Food, Drug, and Cosmetic Act is amended to include requirements for drug approval related to opioids listed in schedule II or III, such as packaging and disposal technologies. Amendments also cover grounds for refusing to approve an Abbreviated New Drug Application. The Federal Food, Drug, and Cosmetic Act is amended to include requirements for drug approval related to opioids listed in schedule II or III, such as packaging and disposal technologies. Amendments also cover grounds for refusing to approve an Abbreviated New Drug Application, including labeling describing technologies, controls, or measures related to packaging or disposal intended to mitigate the risk of abuse or misuse of a drug product. The amended Federal Food, Drug, and Cosmetic Act includes requirements for drug approval related to opioids in schedule II or III, such as packaging and disposal technologies. Measures related to packaging or disposal to mitigate abuse or misuse of a drug product subject to an abbreviated new drug application shall not be seen as changes to labeling or conditions of use that would prevent approval of the application. The amended Federal Food, Drug, and Cosmetic Act includes requirements for drug approval related to opioids in schedule II or III, such as packaging and disposal technologies. The Secretary of Health and Human Services may request or consider various data in making determinations under section 505-2. A report on the effectiveness of in-home controlled substance disposal products and packaging technologies is to be submitted to Congress within 12 months of the Act's enactment. The curr_chunk discusses the effectiveness and availability of in-home controlled substance disposal products and packaging technologies, barriers to their use, federal oversight, and recommendations for preventing diversion of prescribed controlled substances. The curr_chunk provides information on federal oversight of controlled substance packaging technologies, including recommended technologies and their effectiveness in preventing diversion of prescribed substances. The curr_chunk discusses recommendations for federal oversight of in-home controlled substance disposal products and packaging technologies to prevent diversion of prescribed substances. It also addresses the potential role of the Federal Government in evaluating these products for efficacy. The House of Representatives passed the legislation on June 19, 2018, as attested by Karen L. Haas, the Clerk."
}